Literature DB >> 20562880

Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.

Tomonori Nochi1, Yoshikazu Yuki, Haruko Takahashi, Shin-ichi Sawada, Mio Mejima, Tomoko Kohda, Norihiro Harada, Il Gyu Kong, Ayuko Sato, Nobuhiro Kataoka, Daisuke Tokuhara, Shiho Kurokawa, Yuko Takahashi, Hideo Tsukada, Shunji Kozaki, Kazunari Akiyoshi, Hiroshi Kiyono.   

Abstract

Nanotechnology is an innovative method of freely controlling nanometre-sized materials. Recent outbreaks of mucosal infectious diseases have increased the demands for development of mucosal vaccines because they induce both systemic and mucosal antigen-specific immune responses. Here we developed an intranasal vaccine-delivery system with a nanometre-sized hydrogel ('nanogel') consisting of a cationic type of cholesteryl-group-bearing pullulan (cCHP). A non-toxic subunit fragment of Clostridium botulinum type-A neurotoxin BoHc/A administered intranasally with cCHP nanogel (cCHP-BoHc/A) continuously adhered to the nasal epithelium and was effectively taken up by mucosal dendritic cells after its release from the cCHP nanogel. Vigorous botulinum-neurotoxin-A-neutralizing serum IgG and secretory IgA antibody responses were induced without co-administration of mucosal adjuvant. Importantly, intranasally administered cCHP-BoHc/A did not accumulate in the olfactory bulbs or brain. Moreover, intranasally immunized tetanus toxoid with cCHP nanogel induced strong tetanus-toxoid-specific systemic and mucosal immune responses. These results indicate that cCHP nanogel can be used as a universal protein-based antigen-delivery vehicle for adjuvant-free intranasal vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562880     DOI: 10.1038/nmat2784

Source DB:  PubMed          Journal:  Nat Mater        ISSN: 1476-1122            Impact factor:   43.841


  31 in total

1.  Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis.

Authors:  Y Yuki; Y Byun; M Fujita; W Izutani; T Suzuki; S Udaka; K Fujihashi; J R McGhee; H Kiyono
Journal:  Biotechnol Bioeng       Date:  2001-07-05       Impact factor: 4.530

Review 2.  Generation of improved mucosal vaccines by induction of innate immunity.

Authors:  E C Lavelle
Journal:  Cell Mol Life Sci       Date:  2005-12       Impact factor: 9.261

Review 3.  Mucosal vaccine development for botulinum intoxication.

Authors:  Kohtaro Fujihashi; Herman F Staats; Shunji Kozaki; David W Pascual
Journal:  Expert Rev Vaccines       Date:  2007-02       Impact factor: 5.217

4.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 5.  Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.

Authors:  Robert Belshe; Min-Shi Lee; Robert E Walker; Jeffrey Stoddard; Paul M Mendelman
Journal:  Expert Rev Vaccines       Date:  2004-12       Impact factor: 5.217

6.  A novel neurotoxoid vaccine prevents mucosal botulism.

Authors:  Ryoki Kobayashi; Tomoko Kohda; Kosuke Kataoka; Hideshi Ihara; Shunji Kozaki; David W Pascual; Herman F Staats; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

7.  Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

Authors:  M P Byrne; T J Smith; V A Montgomery; L A Smith
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

8.  Molecular composition of Clostridium botulinum type A progenitor toxins.

Authors:  K Inoue; Y Fujinaga; T Watanabe; T Ohyama; K Takeshi; K Moriishi; H Nakajima; K Inoue; K Oguma
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

9.  Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.

Authors:  I Takahashi; M Marinaro; H Kiyono; R J Jackson; I Nakagawa; K Fujihashi; S Hamada; J D Clements; K L Bost; J R McGhee
Journal:  J Infect Dis       Date:  1996-03       Impact factor: 5.226

10.  Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.

Authors:  J Xu-Amano; H Kiyono; R J Jackson; H F Staats; K Fujihashi; P D Burrows; C O Elson; S Pillai; J R McGhee
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

View more
  95 in total

1.  Recent advances in nanotechnology based drug delivery to the brain.

Authors:  Li-Na Lin; Qun Liu; Lei Song; Fang-Fang Liu; Jin-Xiu Sha
Journal:  Cytotechnology       Date:  2010-08-11       Impact factor: 2.058

2.  Polymer hydrogels: Chaperoning vaccines.

Authors:  Herman F Staats; Kam W Leong
Journal:  Nat Mater       Date:  2010-07       Impact factor: 43.841

3.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

Review 4.  Hydrogels and scaffolds for immunomodulation.

Authors:  Ankur Singh; Nicholas A Peppas
Journal:  Adv Mater       Date:  2014-08-25       Impact factor: 30.849

5.  Nanomaterials in controlled drug release.

Authors:  Xin-Jun Cai; Ying-Ying Xu
Journal:  Cytotechnology       Date:  2011-07-01       Impact factor: 2.058

Review 6.  Engineering New Approaches to Cancer Vaccines.

Authors:  Naveen K Mehta; Kelly D Moynihan; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2015-07-08       Impact factor: 11.151

Review 7.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 8.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

9.  Hyaluronic Acid-Based Nanogels Produced by Microfluidics-Facilitated Self-Assembly Improves the Safety Profile of the Cationic Host Defense Peptide Novicidin.

Authors:  Jorrit J Water; YongTae Kim; Morten J Maltesen; Henrik Franzyk; Camilla Foged; Hanne M Nielsen
Journal:  Pharm Res       Date:  2015-03-27       Impact factor: 4.200

Review 10.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.